Annual Report

Overview

The report presents Lupin's FY2017 performance as a year of record growth, with consolidated sales of ₹ 171,198 million and a 24% increase over the prior year. It highlights ₹ 23,101 million of R&D investment, representing 13.5% of global revenues, alongside a global pharmaceutical platform spanning more than 100 countries. Social impact is centered on LHWRF, whose programs reached 2.8 million people across 3,463 villages in eight Indian states.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017
Period: Ends 31 March 2017
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services